Ozempic (semaglutide) is not currently FDA-approved specifically for weight loss at any dose; it is approved in the United States as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. In contrast, Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. While some healthcare providers may prescribe Ozempic "off-label" for weight loss, this is not an FDA-approved use. The distinction between these two drugs is important for understanding coverage, dosing, and expected outcomes.
What FDA approval means for Ozempic and Wegovy
FDA approval indicates that a drug has been reviewed for safety and effectiveness for a specific intended use in a particular population. For semaglutide products, different dosages, indications, and brand names correspond to different regulatory pathways. Below is a compact comparison of the two major FDA-authorized semaglutide products relevant to weight and diabetes.
Quick comparison of semaglutide products
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Brand name | Ozempic | FDA label |
| Active ingredient and dose | Semaglutide, most commonly 0.5 mg or 1 mg once weekly | FDA label |
| Primary FDA indication | Type 2 diabetes management | FDA prescribing information |
| Weight-loss indication | Not approved | FDA communications |
| Brand name | Wegovy | FDA label |
| Active ingredient and dose | Semaglutide 2.4 mg once weekly | FDA label |
| Primary FDA indication | Chronic weight management | FDA prescribing information |
| Weight-loss indication | Approved for obesity and overweight with weight-related conditions | FDA communications |
Uses of Ozempic in clinical practice
Ozempic is primarily prescribed to adults with type 2 diabetes to help control blood sugar when diet and exercise alone are insufficient. In this context, it works by mimicking a hormone that targets areas of the brain involved in glucose regulation and appetite. Some people experience modest weight changes while using Ozempic for diabetes, but this is a secondary effect rather than the intended therapeutic outcome. Off-label use—when a clinician prescribes a medication for a condition not specified on the FDA label—is common in medicine; however, it does not imply FDA approval for that use.
Off-label prescribing and patient expectations
Off-label prescribing is legal and can be appropriate based on clinical judgment and emerging evidence. When Ozempic is used for weight loss, a clinician may consider factors such as medical history, cardiovascular risk, and metabolic health. Patients should discuss realistic expectations, potential benefits, and possible side effects with their provider. Being clear about whether a treatment is FDA-approved for weight loss helps ensure that patients understand the evidence base, reimbursement considerations, and follow-up plan.
Wegovy: the FDA-approved option for weight loss
Wegovy contains a higher dose of semaglutide and is specifically authorized for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or dyslipidemia. Dosing is titrated gradually to reduce gastrointestinal side effects, and treatment is intended to be used alongside a reduced-calorie meal plan and increased physical activity. Clinical trials demonstrated meaningful weight loss compared with placebo when used as directed.
Potential confusion between Ozempic and Wegovy
The similarity in names, active ingredient, and dosing schedules can create confusion. In clinical settings, specifying the exact product, dose, and indication reduces the risk of prescribing or dispensing errors. Because of increased demand for semaglutide for weight loss, some people may seek Ozempic for this purpose without realizing that Wegovy is the FDA-approved option at the necessary dose. Understanding the regulatory status helps patients advocate for appropriate care and coverage.
Coverage, cost, and medical necessity
Insurance coverage often depends on the FDA-approved indication and the individual plan’s policies. Plans are more likely to cover a medication when it is used in an approved population and medical necessity is documented. Using a drug off-label for weight loss may require prior authorization or result in higher out-of-pocket costs. People should review their plan details and talk with their clinician and pharmacy about what is covered and what documentation may be needed.
Safety, side effects, and follow-up
Semaglutide products can cause side effects, particularly gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation. These are often dose-dependent and may improve over time as the dose is increased gradually. People with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 should not use semaglutide. Cardiovascular outcomes have been studied in people with type 2 diabetes, but patients considering these medications for weight loss should discuss individual risks and benefits with their clinician. Regular follow-up supports safe titration, monitoring for adverse effects, and reinforcing lifestyle behaviors.
When to consider talking with a clinician
If you are considering semaglutide for weight management, schedule a visit with a qualified healthcare provider for a full assessment. Bring a list of current medications, medical conditions, and weight-loss goals. Ask whether you meet criteria for an FDA-approved option like Wegovy, or whether an off-label approach with Ozempic might be appropriate for your situation. This conversation can help align treatment with evidence, safety, and personal health priorities.